| Bioactivity | Ixazomib-13C2,15N is 13C and 15N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM)[1]. |
| Formula | C1213C2H19BCl2N15NO4 |
| Molar Mass | 364.01 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Friedman JR, et al. Anticancer Activity of Natural and Synthetic Capsaicin Analogs. J Pharmacol Exp Ther. 2018 Mar;364(3):462-473. |
Ixazomib-13C2,15N
CAS: F: C1213C2H19BCl2N15NO4 W: 364.01
Ixazomib-13C2,15N is 13C and 15N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.